Syncom Formulations (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
SYNCOMF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 5.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syncom Formulations reported strong FY25 results with standalone revenue from operations rising 79% to Rs. 46,284.93 lakhs (vs Rs. 25,835.96 lakhs in FY24). Standalone profit after tax more than doubled to Rs. 4,887.18 lakhs (vs Rs. 2,362.32 lakhs), with EPS at Rs. 0.57 versus Rs. 0.32. Consolidated revenue grew about 77% to Rs. 46,501.26 lakhs and consolidated PAT rose to Rs. 4,943.46 lakhs. The pharmaceutical drugs and formulations segment continues to be the main driver, contributing over 97% of revenue. The company also sharply reduced its standalone borrowings from Rs. 7,165 lakhs to Rs. 404 lakhs, and operating cash flow turned positive at Rs. 2,331 lakhs (vs negative Rs. 594 lakhs last year). The statutory auditor, Sanjay Mehta & Associates, issued an unmodified (clean) opinion on both standalone and consolidated results.
A standout year with nearly doubled profits and major debt reduction signals strong operational and financial health for shareholders. The clean audit report and positive operating cash flow should be viewed positively, though the very low cash balance (Rs. 69 lakhs standalone) at year-end reflects aggressive debt repayment rather than liquidity stress.